Pregnancy and Crohn's disease: Concerns and assurance of medical therapy

Reezwana Chowdhury, Sunanda V. Kane

Research output: Contribution to journalReview articlepeer-review


Approximately 50% of patients with inflammatory bowel disease including both Crohn's disease and ulcerative colitis are female with many being diagnosed and treated during their reproductive years. It is important for women to be in remission prior to and during pregnancy. There have been many advances in the treatment of inflammatory bowel disease, including new therapies. In this review, we summarize the currently approved medications for Crohn's disease and their safety in pregnancy and postpartum. The totality of evidence suggests that the majority of therapies are low-risk before and during pregnancy, and should be continued to control maternal disease.

Original languageEnglish (US)
Article numbergoac055
JournalGastroenterology Report
StatePublished - 2022


  • Crohn's disease
  • anti-TNF
  • biologics
  • inflammatory bowel disease
  • lactation
  • pregnancy
  • teratogenicity

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Pregnancy and Crohn's disease: Concerns and assurance of medical therapy'. Together they form a unique fingerprint.

Cite this